In another single-center study of 137 patients with HER2-positive metastatic breast cancer treated with trastuzumab, a slight trend toward shorter OS in the subgroup of patients with PIK3CA mutations was observed, yet PTEN loss was associated with a significantly shorter survival time.
← all excerpts
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone.
1
—
—